U.S. Capital Wealth Advisors LLC Trims Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

U.S. Capital Wealth Advisors LLC trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 29.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,277 shares of the pharmaceutical company’s stock after selling 941 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $917,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of VRTX. Northwest Investment Counselors LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter valued at $25,000. Highline Wealth Partners LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter valued at $27,000. Dunhill Financial LLC boosted its holdings in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares during the period. Legacy Investment Solutions LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter valued at $33,000. Finally, Truvestments Capital LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter valued at $35,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Stock Up 2.5 %

VRTX stock opened at $482.28 on Wednesday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The firm has a 50 day moving average of $434.73 and a 200 day moving average of $462.62. The stock has a market capitalization of $124.20 billion, a PE ratio of -242.35, a price-to-earnings-growth ratio of 2.39 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same quarter in the previous year, the firm earned $3.67 EPS. The firm’s revenue was up 11.6% compared to the same quarter last year. Sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $480.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Royal Bank of Canada lifted their price objective on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Jefferies Financial Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $500.00 to $550.00 in a report on Monday, December 9th. Finally, StockNews.com downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $502.58.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.